Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.
1008 Data Byte RADx
BioCentury & Infogram


Data Bytes: RADx funding recipients

Oct 8, 2020 | 11:52 PM GMT

NIH and BARDA granted six additional awards to COVID-19 diagnostics developers this week, bringing its total investment in the RADx Initiative for scale-up and manufacturing of new COVID-19 testing technologies to $476.4 million across 22 projects.

Launched in April, the Rapid Acceleration of Diagnostics (RADx) Initiative is a $500 million national technology development competition designed to fuel the development of rapid and easy-to-use COVID-19 tests.

The most recent contracts, issued via RADx’s third round of funding, were awarded to Ellume USA LLC, Luminostics Inc., Quanterix Corp. (NASDAQ:QTRX),  Flambeau Diagnostics, Visby Medical Inc. and Ubiquitome.

Three of the six new contracts will support development of antigen tests. A study published in medRxiv this week by Becton Dickinson and Co. (NYSE:BDX) and Johns Hopkins University scientists suggests antigen tests for COVID-19 do a better job of predicting which patients are infectious than PCR tests.

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers